

---

**Lab Dept:** Serology

**Test Name:** ACETYLCHOLINE RECEPTOR (MUSLCE AChR)  
BINDING ANTIBODY

---

***General Information***

**Lab Order Codes:** ABIN

**Synonyms:** Acetylcholine Receptor (AChR) Antibodies, Serum; ACh Receptor (Muscle) Binding Ab; AChR; Myasthenia Gravis Ab

**CPT Codes:** 83519 – Immunoassay, analyte, quantitative; by radiopharmaceutical technique (eg, RIA)

**Test Includes:** AChR Binding Antibody reported in nmol/L.

---

***Logistics***

**Test Indications:** This is the primary diagnostic test for myasthenia gravis.

**Lab Testing Sections:** Serology - Sendouts

**Referred to:** Mayo Clinic Laboratories (MML Test: ARBI)

**Phone Numbers:** MIN: 612-813-6280

STP: 651-220-6550

**Test Availability:** Daily, 24 hours

**Turnaround Time:** 4 – 6 days – test is set up Sunday - Friday

**Special Instructions:** Sera will be kept for one month

---

***Specimen***

**Specimen Type:** Blood

**Container:** SST (Gold, marble or red)

**Draw Volume:** 3 mL blood

**Processed Volume:** 1 mL serum

**Collection:** Routine blood collection

**Special Processing:** Lab Staff: Centrifuge specimen, remove serum aliquot into screw-capped round bottom plastic vial. Store and ship at refrigerated temperatures. Forward promptly.

**Patient Preparation:** None

**Sample Rejection:** N/A

---

### ***Interpretive***

**Reference Range:** <0.02 nmol/L

Interpretation: Values above 0.02 nmol/L are consistent with the diagnosis of acquired MG, provided that clinical and electrophysiological criteria support that diagnosis.

The assay for muscle AChR binding antibodies is positive in approximately 90% of nonimmunosuppressed patients with generalized MG.

The frequency of antibody detection is lower in MG patients with weakness clinically restricted to ocular muscles (71%) and antibody titers are generally low in ocular MG (eg, 0.03 – 1.0 nmol/L).

Results may be negative in the first 12 months after symptoms of MG appear or during immunosuppressant therapy. Note: in follow-up of seronegative patients with adult-acquired generalized MG, 17.4% seroconvert to positive at 12 months (ie, seronegativity rate at 12 months is 8.4%). Of persistently seronegative patients, 38% have muscle-specific kinase (MuSK) antibody.

In general, there is not a close correlation between antibody titer and severity of weakness, but in individual patients, clinical improvement is usually accompanied by decrease in titer.

**Critical Values:** N/A

**Limitations:** Positive results for AChR Binding or striational antibodies are found in 13% of patients with Lambert-Eaton myasthenic syndrome (LES). This does not mean that MG and LES coexist. Antibodies to P/Q type calcium channels are found in 95% of LES patients, but not in MG, except in very rare paraneoplastic cases related to small-cell lung carcinoma.

Positive results are frequently found with autoimmune liver disease.

Magnitude of the result is not useful for predicting severity of MG.

The presence of alpha-bungarotoxin antibodies may interfere with this assay.

**Methodology:** Radioimmunoassay (RIA)

**References:**

[Mayo Clinic Laboratories](#) September 2019